Designed for patients with intact coagulation, PERCLOT powder is said to be a passive, absorbable hemostatic powder that stops mild bleeding by offering a mechanical barrier using a gelled adhesive matrix


Baxter launches PERCLOT absorbable haemostatic powder in the US. (Credit: Narupon Promvichai from Pixabay)

American healthcare company Baxter International has introduced its ready-to-use PERCLOT absorbable haemostatic powder in the US to address mild bleeding.

Designed for patients with intact coagulation, PERCLOT powder is said to be a passive, absorbable haemostatic powder that stops mild bleeding.

According to Baxter, the powder is made from absorbable polysaccharide granules which quickly absorb water and generate a gelled adhesive matrix to offer a mechanical barrier against future bleeding. This leads to the accumulation of platelets, red blood cells, and coagulation proteins (thrombin and fibrinogen).

Once the clot is formed, PerClot granules are broken down and absorbed by the body.

Baxter said that PERCLOT powder can be used to control bleeding during open and laparoscopic surgical procedures, including gynecologic, general, urology, and cardiovascular.

PERCLOT improves doctors’ ability to maximise patient care by treating a larger variety of intraoperative bleeding, the healthcare company claimed.

Baxter said that the potential to manage intraoperative bleeding helps to lower overall healthcare costs, minimise blood transfusions, and avoid major complications for patients.

Baxter advanced surgery president Steve Wallace said: “PERCLOT is a strong complement to Baxter’s leading haemostat portfolio.

“The launch of PERCLOT in the US allows us to provide surgeons with a full range of active and passive haemostatic products for bleeding control, helping to optimise care for their patients.”

For the launch, Baxter is collaborating with clients from various hospitals across the US to include PERCLOT in their standard of care for low-level bleeding.

The healthcare firm acquired certain assets related to PerClot Polysaccharide Hemostatic System from US-based CryoLife, now known as Artivion, for up to $60.8m in July 2021.

Since then, Baxter has expanded the product’s global commercial footprint. Currently, the product is being sold in more than 35 countries.

In May this year, Artivion received the premarket application (PMA) approval for Perclot System from the US Food and Drug Administration (FDA). The firm then transferred the PMA to Baxter as per their previously signed agreements.